|
CLINICAL SCALES
Interactive, mobile-ready Depression Clinical Scales
Includes: Patient Health Questionnaires 7-item General Anxiety Disorder Assessment Major Depression Inventory Hamilton Anxiety Scale Geriatric Depression Assessment
PATIENT RESOURCES
www.nlm.nih.gov -
3/20/13
www.ahrq.gov -
10/4/12
www.ahrq.gov -
9/26/12
www.ahrq.gov -
7/22/12
www.ahrq.gov -
6/20/12
www.ahrq.gov -
4/29/12
CLINICAL TRIALS
psychiatryonline.org -
11/30/13
neuro-oncology.oxfordjournals.org -
3/25/13
neuro-oncology.oxfordjournals.org -
3/25/13
MEDLINE
pubmed.gov -
1/23/13
23342823 2013 01 24 2013 02 21 0027-9684 104 9-10 2012 Sep-Oct J Natl Med Assoc 463-4 Drakes Wilma A WA eng Comment Letter United States J Natl Med Assoc 7503090 0027-9684 IM J Natl Med Assoc. 2011 Jul; 103( 7): 548-57 21999029 ethnology.
pubmed.gov -
1/4/13
Depression is the third leading contributor to the worldwide burden of disease. We assessed the nature and severity of experienced and anticipated discrimination reported by adults with major depressive disorder worldwide. Moreover, we investigated whether experienced discrimination is related to clinical history, provision of health care, and disclosure of diagnosis and whether anticipated discrimination is associated with disclosure and previous experiences of discrimination.|In a cross-sectional survey, people with a diagnosis of major depressive disorder were interviewed in 39 sites (35 countries) worldwide with the discrimination and stigma scale (version 12; DISC-12). Other inclusion criteria were ability to understand and speak the main local language and age 18 years or older. The DISC-12 subscores assessed were reported discrimination and anticipated discrimination. Multivariable regression was used to analyse the data.|1082 people with depression completed the DISC-12. Of
pubmed.gov -
12/31/12
The sequencing of the human genome in the early days of this millennium was greeted with great fanfare as this accomplishment was expected to revolutionize medicine and result in individualized treatments based on the genetic make-up of the patient. The ultimate promise of personalized medicine would be fulfilled with the identification of disease biomarkers that would be widely available for use in diagnosis and treatment. Progress, however, has been slow in providing disease biomarkers or approved diagnostic tests. This is true for major depressive disorder (MDD), despite its prevalence in the general population and the widespread acceptance of its biological basis. Studies using strategies like genome-wide association and candidate gene analyses have identified a number of possible biomarkers of MDD, including serum levels of neurotrophic factors, inflammatory cytokines and HPA axis hormones, but none have proven sufficiently powerful for clinical use. The lack of biologically
pubmed.gov -
12/31/12
Cognitive impairment, in particular of attention and memory, is often reported by patients suffering from major depressive disorder (MDD) and deficits in attention are part of the current diagnostic criteria of MDD. Objectively measured cognitive deficits associated with MDD have been described in many studies. They have been conceptualized as an integral facet and epiphenomenon of MDD. However, evidence accumulated in recent years has challenged this notion and demonstrated that in a subset of patients the degree of cognitive deficits cannot be accounted for by the severity of depression. In addition, in some patients cognitive deficits persist despite resolution of depressive symptomatology. It is plausible to assume that cognitive deficits contribute to functional impairment even though supportive data for such a relationship are lacking. However, the exact association between cognitive deficits and major depression and the clinical and neurobiological characteristics of patients
pubmed.gov -
12/14/12
Measuring disease and injury burden in populations requires a composite metric that captures both premature mortality and the prevalence and severity of ill-health. The 1990 Global Burden of Disease study proposed disability-adjusted life years (DALYs) to measure disease burden. No comprehensive update of disease burden worldwide incorporating a systematic reassessment of disease and injury-specific epidemiology has been done since the 1990 study. We aimed to calculate disease burden worldwide and for 21 regions for 1990, 2005, and 2010 with methods to enable meaningful comparisons over time.|We calculated DALYs as the sum of years of life lost (YLLs) and years lived with disability (YLDs). DALYs were calculated for 291 causes, 20 age groups, both sexes, and for 187 countries, and aggregated to regional and global estimates of disease burden for three points in time with strictly comparable definitions and methods. YLLs were calculated from age-sex-country-time-specific estimates of
CONNECT WITH US
|
|
||||||||||||||
Astrocytic signaling to adenosine receptors results in the robust reduction of depressive-like behaviors associated with sleep deprivation, according to researchers.
The diagnosis of depression in the context of diabetes and other chronic medical conditions can be challenging.
Major depression is a common chronic illness within the general US population. What is the approximate prevalence for MDD in the US population?
What are the advantages of adjunctive benzodiazepine therapy in comorbid depression and anxiety? Which therapy has the strongest evidence base for treating patients with late-life depression? These and more in this quiz.
Which antidepressants are associated with the highest rates of sexual dysfunction in patients treated for depression? This and more in this week's quiz.
Efficacy and safety of bupropion and SSRIs in comorbid depression and restless legs syndrome? Which psychiatric scale has proven useful for tracking depression when Electroconvulsive Therapy is involved? These questions and more in this week's Mine Your Mind quiz.Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy